Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

The Lancet · 2011 · 3.1K citations · Full text

Medicine, Endocrinology, Oncology +15

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

Anthony Howell, Jack Cuzick, M Baum et al. · The Lancet · 2005 · 2.3K citations

Medicine, Oncology, Breast Oncology +6

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Medicine, Endocrinology, Oncology +14

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · New England Journal of Medicine · 2004 · 1.8K citations · Full text

Pharmacy, Endocrinology, Oncology +13

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

Dawn L. Hershman, Theresa Shao, Lawrence H. Kushi et al. · Breast Cancer Research and Treatment · 2010 · 880 citations

Medicine, Oncology, Breast Oncology +15